Elmer 2017 US Patent
From Bioblast
Revision as of 09:16, 3 March 2020 by Gnaiger Erich (talk | contribs)
| Elmer E, Hansson MJ, Ehinger JK, Piel S, Moss S (2017) Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex I-related impairment of mitochondrial oxidative phosphorylation. US Patent US20170100359 A1. |
Elmer E, Hansson MJ, Ehinger JK, Piel S, Moss S (2017) US Patent
Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.
• Bioblast editor: Kandolf G • O2k-Network Lab: SE Lund Elmer E
Labels: MiParea: Respiration, Pharmacology;toxicology
Organism: Human
Tissue;cell: Heart, Blood cells, Fibroblast, Macrophage-derived, Platelet
Preparation: Intact cells
Coupling state: LEAK, ROUTINE, OXPHOS, ET
Pathway: S, ROX
HRR: Oxygraph-2k
Labels, PBMC
